Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia
Oncotarget. 2024 Apr 8;15:248-254. doi: 10.18632/oncotarget.28579.ABSTRACTAcute myeloid leukemia (AML) is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the bone marrow. Conventional therapies include chemotherapy and bone marrow stem cell transplantation; however, they are often associated with poor prognosis. Notably, growth hormone-releasing hormone (GHRH) receptor antagonist MIA-602 has been shown to impede the growth of various human cancer cell lines, including AML. This investigation examined the impact of MIA-602 as monotherapy and in combination with Doxorubicin on three Doxorub...
Source: Oncotarget - April 8, 2024 Category: Cancer & Oncology Authors: Simonetta I Gaumond Rama Abdin Joel Costoya Andrew V Schally Joaquin J Jimenez Source Type: research
